1月15日早盘，港股市场关键指数集体调整，恒生科技指数盘中跌超1.5%，恒生指数冲高回落，消费、 医药、科技等板块领跌，港股通医疗ETF（520510）一度跌超2%。 受AI医疗应用加速落地、BD交易密集落地、脑机接口利好消息等影响，港股医疗板块近期表现持续强 势，港股通医疗ETF连续8日收涨，年内涨幅一度突破20%，在全市场ETF中涨幅领先。 从今日盘面来看，阿里健康、晶泰控股、脑动极光、方舟健客等AI医疗、脑机接口相关概念股领跌。 中邮证券表示，"AI+医疗"行业人工智能解决方案的全球市场规模预计将由2022年的137亿美元增至 2030年的1553亿美元，CAGR为35.5%，中国市场在2030年有望达到168.3亿美元，行业存在爆发式增长 机会。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com ...

Group 1 - The 44th J.P. Morgan Healthcare Conference is set to take place in San Francisco on January 12, 2026, featuring multiple Chinese innovative pharmaceutical companies [1] - Key speakers include WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary, along with innovative drug companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech [1] - A total of 17 companies, including Hengrui Medicine, Baillie Gifford, and 3SBio, will participate in the Asia-Pacific session, highlighting the growing presence of Chinese firms in the global market [1] Group 2 - Guotai Junan Securities views the conference as a critical platform for domestic pharmaceutical companies to showcase their core molecular product capabilities and advance overseas business development collaborations [1] - The industry is transitioning back to a phase of global value verification for products, driven by advancements in global clinical trials, significant data releases, and an optimized competitive landscape [1] - Huayuan Securities indicates that the Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth trajectories for companies [1] Group 3 - The Hong Kong Stock Connect Medical ETF (520510) has over 27% weight in WuXi-related companies and more than 25% exposure to AI healthcare [2] - The Hang Seng Medical ETF (159892) focuses on the innovative drug sector and is the largest in scale within its index [3]

Core Viewpoint - The A-share market concluded 2025 with strong gains, characterized by a structural bull market driven by hard technology sectors like artificial intelligence, leading to significant performance in industries such as electronics and communications [1] Group 1: Market Performance - The ChiNext Index surged by 49.57% for the year, leading the market, while the Shanghai Composite Index rose by 18.41%, marking its largest annual increase in nearly six years [1] - The total scale of the public fund industry in 2025 surpassed 37 trillion yuan, indicating a new milestone for the asset management sector [1] Group 2: Equity Fund Performance - In 2025, the active equity segment of the company saw over 30 products ranking among the top performers, with 31 active equity funds achieving annual returns exceeding 50%, including 12 funds surpassing 80% and 5 funds doubling their returns [2] - The company ranked second among 13 large public fund companies in terms of active management returns for equity products over the past three years, showcasing strong mid-to-long-term performance [2] Group 3: Technology and Healthcare Investments - The "Fuguo Technology Performance Team" excelled in the technology growth sector, with the Fuguo Innovation Technology A fund achieving a return of 133.99%, ranking second in its category [3] - In the healthcare investment space, the company focused on innovative drugs and medical devices, with the Fuguo Medical Innovation A fund returning 67.70%, ranking second in its category [3] Group 4: Fixed Income Performance - The fixed income team demonstrated strong performance in a challenging market environment, with the company ranking in the top 25% of peers over three, five, and seven-year periods [4] - Notable fixed income products included Fuguo Jiuli Stable Allocation A, which achieved a return of 37.04%, ranking second in its category [4] Group 5: Quantitative Investment - The company expanded its quantitative investment tools, with over 80 ETF products and a total scale exceeding 250 billion yuan, marking a significant increase of over 120 billion yuan in 2025 [6] - Nine quantitative products ranked among the top 10 in their categories, with the Communication Equipment ETF achieving a return of 121.01%, ranking second [6] Group 6: Future Outlook - The public fund industry is entering a critical phase focused on high-quality development centered on investor interests, with the company committed to long-term investment principles and enhancing its research systems across equity, fixed income, and quantitative platforms [7]

Group 1 - The A-share market opened strong in 2026, with 31 ETFs rising over 5%, marking a return to 4000 points after 34 days and achieving a record 12 consecutive days of gains, the longest since 1993 [1] - Key sectors driving the market include brain-computer interfaces, AI applications, commercial aerospace, memory chips, and innovative pharmaceuticals, with insurance stocks also performing well [1] - The global memory chip stocks reached new highs, with the Korea-China semiconductor ETF leading with an 8.45% increase, as Samsung and SK Hynix seek to raise server memory chip prices by 70% [1] Group 2 - Neuralink, Elon Musk's brain-computer interface company, plans to begin large-scale production of its devices in 2026, with a focus on automating surgical procedures to enhance efficiency and reduce costs [5] - Goldman Sachs' macro report suggests overweighting Chinese stocks in 2026, predicting annual market growth of 15% to 20% driven by AI applications, export trends, and supportive policies [6] - According to招商证券, A-share market is expected to see a net inflow of 1.56 trillion yuan in 2026, supported by public funds, insurance capital, and private equity investments, contributing to a slow bull market [7]

Market Performance - The three major A-share indices collectively rose in the morning session, with the Shanghai Composite Index increasing by 1.07% and returning to the 4000-point level, the Shenzhen Component Index rising by 1.87%, and the ChiNext Index up by 2.15% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.6489 trillion yuan, an increase of 324 billion yuan compared to the previous day [1] - Over 4000 individual stocks in the market experienced gains [1] Sector Performance - Insurance stocks led the gains, while sectors such as brain-computer interfaces and innovative pharmaceuticals saw a surge in limit-up trading [1] - The semiconductor industry chain experienced a significant breakout, with AI applications and commercial aerospace themes also being active [1] - The Hainan Free Trade Zone, stablecoins, and oil sectors faced adjustments [1] ETF Performance - The semiconductor industry chain saw a notable increase, with the Huatai-PB Fund's China-Korea Semiconductor ETF rising by 6.52% [1] - In the Hong Kong stock market, the innovative pharmaceutical sector rebounded strongly, with the Fortune and Huatai-PB Fund's Hong Kong Stock Connect Medical ETF increasing by 6.21% and 5.92%, respectively [1] - Insurance stocks also led in the ETF space, with the GF Fund's Hong Kong Stock Connect Non-Bank ETF rising by 5.25% [1] Declining Sectors - The tourism sector declined, with two tourism ETFs dropping by 2% [1] - The oil and gas sector also saw declines, with the oil and gas ETFs from Huatai-PB falling by 1% and 0.87%, respectively [1]

Group 1 - The brain-computer interface (BCI) sector in A-shares experienced a strong surge on January 5, 2026, with stocks like Botao Bio, Sino Medical, and Xiangyu Medical hitting the 20% daily limit up [1] - The medical device ETF rose by 5.6%, while the Hong Kong medical sector also saw gains, with the Hang Seng Pharmaceutical ETF and Hong Kong Stock Connect Medical ETF increasing by 6% and 5.7%, respectively [1] - Elon Musk's Neuralink announced plans for large-scale production of BCI devices in 2026, marking a significant shift from clinical validation to commercial-scale production [1][3] Group 2 - In 2025, China approved 76 innovative drugs for market, surpassing the 48 approved in 2024, with total transaction amounts for innovative drug licensing exceeding $130 billion and over 150 transactions, both setting historical records [1] - The medical device ETF (562600) tracks the CSI Medical Device Index, with the medical device industry comprising 89% and BCI content at 23.14% [3] - The Hang Seng Pharmaceutical ETF (159892) has a scale of 5.564 billion yuan, with top-weighted stocks including BeiGene [3]

Market Performance - The A-share market returned to 3900 points, with the Shanghai Composite Index rising by 0.69%, the Shenzhen Component Index increasing by 1.47%, and the ChiNext Index up by 2.23% [1] - The total market turnover reached 186.5 billion yuan, an increase of 11.63 billion yuan compared to the previous day [1] Sector Performance - Active sectors included Hainan, storage chips, and precious metals, while the pharmaceutical commercial and film industry sectors experienced adjustments [1] - In the ETF market, the US biotechnology sector saw gains, with the Harvest Fund S&P Biotechnology ETF and the Huatai-PineBridge Fund NASDAQ Biotechnology ETF rising by 5.01% and 4.88%, respectively [1] - The semiconductor sector experienced a broad increase, with the Guotai Fund Semiconductor Equipment ETF, GF Fund Chip Equipment ETF, and Wanji Fund Semiconductor Equipment ETF rising by 4.93%, 4.92%, and 4.82%, respectively [1] - The CPO sector rebounded strongly, with the Guotai Fund Communication ETF and Bosera Fund 5G50 ETF both increasing by 4% [1] - Gold reached a new historical high, with the Huaxia Fund Gold Stock ETF and Ping An Fund Gold Stock ETF rising by 3.7% [1] Hong Kong Market - The Hong Kong medical sector declined, with the Hong Kong Innovative Drug 50 ETF, Hang Seng Biotechnology ETF, Hong Kong Medical ETF, and Hong Kong Stock Connect Medical ETF all falling by 1% [1] - The film sector also weakened, with the film ETF dropping by 1.29% [1]

Group 1 - The A-share market has returned to 3900 points, with the Shanghai Composite Index rising by 0.64%, the Shenzhen Component Index increasing by 1.36%, and the ChiNext Index up by 1.8% [1] - The total market turnover reached 1,198.9 billion yuan, an increase of 95.4 billion yuan compared to the previous day [1] - Stocks related to the Hainan Free Trade Zone experienced a surge, while the semiconductor industry chain saw significant gains, and sectors such as computing hardware, stablecoins, robotics, intelligent driving, and duty-free shops were actively performing [1] Group 2 - In the ETF market, the semiconductor sector saw a broad increase, with funds like GF Fund's Chip Equipment ETF, Guotai Fund's Semiconductor Equipment ETF, and Wanji Fund's Semiconductor Equipment ETF rising over 4% [1] - The CPO sector rebounded strongly, with Guotai Fund's Communication ETF increasing by 4.18% [1] - Gold reached a new historical high, with Huaxia Fund's Gold Stock ETF rising by 3.73% [1] Group 3 - The Hong Kong stock market's healthcare sector declined, with both the Hong Kong Healthcare ETF and the Hong Kong Stock Connect Healthcare ETF falling by 1% [1] - The film and television sector weakened, with the Film and Television ETF dropping by 0.86% [1]

Group 1 - The core viewpoint of the article highlights the recent rebound in the Hong Kong stock market, with the Hang Seng Index rising by 0.75%, the Hang Seng Tech Index increasing by 1.12%, and the Hong Kong Stock Connect Internet Index up by 0.88% [1][16] - The improvement in external liquidity expectations is a significant factor, as U.S. inflation has unexpectedly slowed, strengthening market expectations for the Federal Reserve to lower interest rates next year, which is beneficial for offshore markets like Hong Kong [1][16] - Domestic capital has played a crucial role, with net inflows from southbound funds exceeding 1.4 trillion HKD this year, demonstrating the long-term commitment of mainland investors to Hong Kong assets [1][16] Group 2 - Market sentiment and valuation recovery are evident, as major indices in Hong Kong are now at historically low valuation levels, providing a significant margin of safety [1][16] - The policy environment remains accommodative, with recent economic meetings confirming that a moderately loose monetary policy will continue next year to promote stable economic growth, providing a macro-level confidence foundation for the market [1][16] - The latest report from CITIC Securities indicates that after a unilateral rise in September, the Hong Kong market has experienced fluctuations since October due to overseas macro expectations, with quality assets now entering a high cost-performance ratio zone [1][16] Group 3 - The article discusses various Hong Kong ETFs, including the Hong Kong Internet ETF, which tracks the CSI Hong Kong Internet Index and focuses on leading internet companies through the Stock Connect, benefiting from the core dividends of China's digital economy [3][18] - The Hong Kong Innovation Drug ETF, which tracks the Hang Seng Hong Kong Stock Connect Innovation Drug Select Index, has seen its shares reach a new high of 4.178 billion, reflecting long-term value recognition despite recent adjustments [7][20] - The Hong Kong Medical ETF is highlighted for its low valuation and high growth expectations, with a TTM price-to-earnings ratio of 30.44, which is significantly lower compared to A-shares and U.S. medical sectors, indicating a pricing advantage [12][25]

Group 1 - The healthcare sector is experiencing a surge, with Hong Kong medical ETFs and Hong Kong Stock Connect medical ETFs rising over 2% [1] - The Hong Kong Stock Connect medical ETF tracks the Hong Kong Stock Connect medical theme index, covering three major sub-sectors in healthcare, with over 30% weight in CXO and over 20% in AI healthcare [1] - The Ant Group's AI health application "Antifufu" has seen a significant increase in downloads, reaching over 15 million monthly active users and answering over 5 million health inquiries daily [1] Group 2 - The rise of "Antifufu" is seen as a superficial market reaction, with the underlying transformation driven by AI technology reshaping the pharmaceutical business's service boundaries, operational efficiency, and profit models [2] - The first transformation involves the expansion and deepening of service boundaries to address the "last mile" issues in pharmaceutical commerce [2] - The second transformation focuses on exponential improvements in operational efficiency, restructuring the cost structure of the pharmaceutical business [2] - The third transformation is about diversifying profit models, moving beyond traditional "price difference" profit strategies [2] Group 3 - According to China Merchants Securities, the healthcare technology sector is expected to have limited stocks that will see sustained market performance by 2025, with overall performance lagging behind the high prosperity of the primary market [3] - The current phase of AI penetration in the healthcare industry is still in the value creation formation period, requiring time for technology maturity and organizational adaptation within the healthcare system [3] - Companies with stable performance, deep integration into core workflows, and long-term AI options are more likely to achieve value reassessment [3] Group 4 - Western Securities notes that the pharmaceutical industry has shown performance divergence this year, with medical devices and hospital sectors facing pressure from macroeconomic factors and policy changes [4] - Current valuations in medical equipment, hospitals, offline pharmacies, and traditional Chinese medicine are at historical lows, indicating potential for recovery [4] - The introduction of multiple policies supporting innovative devices and strengthening grassroots medical services suggests significant potential in the pharmaceutical sector [4] - The medical device sector is expected to benefit from domestic equipment exports, innovation, and the recovery of bidding processes [4]